Clinical and sociodemographic features of Puerto Ricans with systemic sclerosis

Ethnicity and Disease

Volumn 20, Issue 1 SUPPL.1, 2010, Pages

  Ríos, Grissel ^a   Mayor, Angel M ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Hispanics; Scleroderma; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CENTROMERE ANTIBODY;

ADULT; CLINICAL ARTICLE; CLINICAL FEATURE; CONFERENCE PAPER; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; HYPOPIGMENTATION; KIDNEY DISEASE; LUNG DIFFUSION CAPACITY; LUNG DISEASE; MALE; PUERTO RICO; PULMONARY HYPERTENSION; QUESTIONNAIRE; RAYNAUD PHENOMENON; SCAR; SYSTEMIC SCLEROSIS;

EID: 80053200032     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. LeRoy EC, Krieg T, Black C, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol. 1988;15(2): 202-205. (Pubitemid 18073738)
2. Huzelmann N, Genth E, Krieg T, et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology. 2008;47(8):1185-1192. (Pubitemid 352038224)
3. Steen VD, Medsger TAJr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11): 2437-2444.
4. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003;29(2):239.
5. Mayes MD, Lacey JVJr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8): 2246-2255.
6. Ferri C, Bernini L, Cecchetti R, et al. Cutaneous and serologic subsets of systemic sclerosis. J Rheumatology. 1991;18(12): 1826-1831.
7. Reveille JD, Fischbach M, McNearney T, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum. 2001;30(5):332-346. (Pubitemid 32298859)
8. McNearney T, Reveille JD, Fischbach M, et al. Pulmonary Involvement in Systemic Sclerosis: Associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Car Res. 2007;57(2):318-326. (Pubitemid 47164096)
9. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23(5):581-590.
10. Clements P, Hurwitz E, Seibold J, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis. Arthritis Rheum. 2000;43(11):2445-2454.
11. Tager RE, Tikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in black South Africans. Rheumatology. 1999;38:397-400. (Pubitemid 29507121)
12. Coral-Alvarado P, Rojas-Villarraga A, Latorre MC, et al. Risk factors associated with pulmonary arterial hypertension in Colombian patients with systemic sclerosis: review of the literature. J. Rheumatology. 2008;35(2): 244-250. (Pubitemid 351281145)
13. Medsger TA, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatology. 1999;26(10):2159-2167. (Pubitemid 29487010)
14. Valentini G, Bencivelli W, Bombardieri S, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis. 2003;62(9):901-903. (Pubitemid 37026505)
15. Valentini G, D'Angelo S, Della Rossa A, Bencivelli W, Bombardieri S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis. 2003; 62(9):904-905. (Pubitemid 37026506)
16. Della Rossa A, Valentini G, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis. 2001;60(5):585-591. (Pubitemid 32493985)
17. McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum. 1989;32(1):54-60. (Pubitemid 19034924)
18. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1 year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176:1026-1034. (Pubitemid 350127847)
19. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, doubleblind placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962-3970. (Pubitemid 44955900)